Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Dec;200(6):770-4; discussion 774-5.
doi: 10.1016/j.amjsurg.2010.07.025.

Risk factors associated with local and in-transit recurrence of cutaneous melanoma

Chee-Chee H Stucky  1 , Richard J Gray, Amylou C Dueck, Nabil Wasif, Susan D Laman, Aleksandar Sekulic, Barbara A Pockaj
Affiliations

Risk factors associated with local and in-transit recurrence of cutaneous melanoma

Chee-Chee H Stucky et al. Am J Surg. 2010 Dec.

Abstract

Background: Understanding the risk factors for local and in-transit recurrences (LR/ITR) may help facilitate methods of prevention, early detection, and treatment.

Methods: A retrospective review of a prospectively collected database was performed on patients diagnosed with single-lesion cutaneous melanoma. Clinical and pathologic characteristics of the tumors were evaluated.

Results: Of 225 patients, 10% had LR/ITR. Patients with LR/ITR were older (P = .0002), had thicker tumors (P = .018), and positive angiolymphatic invasion more frequently (P < .0001). An increased tumor mitotic rate (TMR) was more common in LR/ITRs (P = .051). On univariate logistic regression, age, thickness, TMR of 11/mm(2) or greater, and angiolymphatic invasion were all significant risk factors for LR/ITR. Multivariate logistic regression showed age, thickness, and angiolymphatic invasion were the only significant risk factors.

Conclusions: Older patients with thicker tumors and angiolymphatic invasion appear to be at higher risk for LR/ITR. Such patients warrant consideration of preventative strategies and should receive close clinical follow-up evaluation for early recurrence.

PubMed Disclaimer

LinkOut - more resources